Page 89 - Biomarkers for risk stratification and guidance in heart failure

Chapter 4
Table 2 Baseline characteristics comparing patients with preserved vs. reduced left ventricular ejection fraction (LVEF)
Age (years)
Age ≥75 years
Male gender
BMI (kg/m2 ) (n = 1546)
Hypertension (n = 2019) Renal failure (n = 1875) CVI/TIA (n = 1876)
Diabetes COPD
PVD (n = 1688)
Cancer (n = 1474) CVI/TIA, COPD or
diabetes (n = 1876) CVI/TIA, COPD, diabetes or PVD (n = 1688)
NYHA ≥ III
LVEF (%) (n = 1667)
HFrEF
Creatinine (μmol/L)
(n = 2016) NT-proBNP (pg/mL)
(n = 1758)*
ACE-inhibitor (n = 1866)
Spironolactone
(n = 1866)
Loop diuretic (n = 1866)
(NT-pro)BNP-guided therapy
77.2 ± 9.3 200 (68%) 121 (41%) 27.2 ± 5.2 (n = 257) 216 (73%) of 295 117 (40%)
58 (20%)
89 (30%) 44 (15%) 60 (21%) of 285
32 (15%) of 207 152 (51%)
163 (57%)
149 (50%) 55 \[50 - 60\] (n = 289)
0 (0%)
111
\[87 - 142\]
2061
\[1350 - 3933\]
207 (70%) 55 (19%) 195 (66%) 81 (27%) 274 (93%) 144 (49%)
72.6 ± 10.7 <0.001 850 (49%) <0.001 1215 (70%) <0.001 26.3 ± 4.6 0.01 (n = 1289)
982 (57%) <0.001 of 1724
395 (25%) <0.001 of 1579
253 (16%) 0.13 of 1580
549 (32%) 0.57 289 (17%) 0.43
174 (12%) <0.001 of 1403
143 (11%) 0.09 of 1267
798 (51%) 0.79
745 (53%) 0.21
980 (57%) 0.04 30 \[23 - 35\] -
(n = 1378)
1731 - (100%)
108 0.35 \[88 - 140\]
(n = 1720)
2811 <0.001 \[1467 - 5481\]
(n = 1462)*
1179 (75%) 0.06 of 1570
332 (21%) 0.32 of 1570
1184 (75%) 0.001 of 1570
407 (26%) 0.61 of 1570
1349 (86%) 0.002 of 1570
862 (50%) 0.75
64.7 ± 8.7 0 (0%) 713 (73%) 27.6 ± 5.0 (n = 747) 517 (53%)
182 (21%) of 863 120 (14%) of 864
331 (34%) 170 (17%)
95 (12%) of 764
57 (9%) of 667
439 (51%) of 864
401 (52%) of 764
504 (52%) 30 \[22 - 37\] (n = 771) 881 (90%)
103
\[85 - 132\] (n = 972) 2077
\[1110 - 4026\] (n = 813)* 660 (76%) of 863
191 (22%) of 863
662 (77%) of 863
265 (31%) of 863
757 (88%) of 863
493 (50%)
81.2 ± 4.0 - 1050 (100%) -
ARB (n = 1866)
-Blocker (n = 1866)
Numbers are n (%) unless otherwise indicated.
* Excluding patients from UPSTEP trial.
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; BMI, body mass index; CVI, cerebrovascular insult; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; NYHA, New York Heart Association classification; ACE, angiotensin- converting enzyme; ARB, angiotensin-II receptor blocker; (NT-pro)BNP, (N-terminal pro-)brain natriuretic peptide.
88
623 (59%) 25.3 ± 4.2 (n = 799) 681 (65%) 1042
330 (33%) 1012
191 (19%) 1012
307 (29%) 163 (16%) 139 (15%) 924
118 (15%) 807
551 (50%) 1012
850 (81%) <0.001 114 \[90 - 146\] <0.001
(n = 1044)
3256 <0.001
\[1818 - 6323\]
(n = 945)*
726 (72%) of 0.04 1003
196 (20%) of 0.17 1003
717 (71%) of 0.01 1003
223 (22%) of <0.001 1003
866 (86%) of 0.38 1003
513 (49%)
<0.001 <0.001
of <0.001 of <0.001 of 0.004
0.03
0.26 of 0.12
of <0.001 of 0.89 of 0.33
507 (55%)
924
625 (60%)
35 \[25 - 45\] <0.001 (n = 896)
<0.001
0.47
HFpEF (n = 296)
HFrEF (n=1731)
P
Age <75 years (n = 977)
Age ≥75 years (n=1050)
P